Threshold Pharmaceuticals - Worst Pharma Stocks of 2007
Company: Threshold Pharmaceuticals
Starting stock price: $3.41
Ending stock price: $0.53
Percent Change: -84.46%
Details: Threshold had a tough time of it in 2006, and the situation didn't improve in 2007 when the company halted a Phase II trial of glufosfamide for small cell lung cancer after it found that patients weren't responding to the drug. Just two weeks later Threshold chopped its 44-person workforce down to 32, concentrating on its hypoxia-activated prodrug program and the ongoing clinical trials of glufosfamide for pancreatic cancer and Phase II for ovarian cancer. Earlier this year the company said the pancreatic cancer trial would continue, but the ovarian cancer trial has been abandon due to lack of efficacy.
More News:
Threshold slashes staff in effort to cut burn rate. Report
Threshold halts lung cancer study. Report
Threshold delays release of glufosfamide analysis. Report
Threshold slashes staff in wake of quarterly loss. Report
Threshold shares drop after Phase III suspension. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: